RSPO Binding Agents and Uses Thereof
AssigneeOncoMed Pharmaceuticals, Inc.
InventorsAustin L. GURNEY, Fumiko Takada Axelrod, Timothy Charles Hoey, Cecile Chartier-Courtaud
Life of this patent
Estimating the term…
Loading patent…
AssigneeOncoMed Pharmaceuticals, Inc.
InventorsAustin L. GURNEY, Fumiko Takada Axelrod, Timothy Charles Hoey, Cecile Chartier-Courtaud
Estimating the term…
The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
1-173. (canceled)
An isolated antibody that specifically binds human R-spondin 1 (RSPO1), which comprises:
A hybridoma cell line having ATCC deposit number PTA-11970.
An isolated antibody that specifically binds human R-spondin 2 (RSPO2), which comprises:
A hybridoma cell line having ATCC deposit number PTA-12021.
A polypeptide comprising a sequence selected from the group consisting of:
An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:
Dependencies are inferred from the claim text.